<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104637</url>
  </required_header>
  <id_info>
    <org_study_id>1022</org_study_id>
    <nct_id>NCT00104637</nct_id>
  </id_info>
  <brief_title>Sildenafil for Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Crossover Study of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kawut, Steven, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kawut, Steven, MD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if sildenafil improves the exercise capacity and
      lung function of patients with chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic obstructive pulmonary disease (COPD) suffer from impaired exercise
      capacity and quality-of-life, largely related to shortness of breath. Many of the therapies
      currently available for COPD are aimed at improving these factors. Exercise capacity is
      limited in part by high blood pressure in the blood vessels in the lungs. Sildenafil, also
      known as Viagra, is an FDA-approved therapy for male erectile dysfunction. One of its effects
      is to relax (or open) the lung vessels, thereby lowering the blood pressure in the lungs. We
      hypothesize that sildenafil will result in an improvement in exercise capacity,
      quality-of-life, and shortness of breath.

      Enrolled subjects will receive sildenafil or placebo for 4 weeks followed by exercise tests,
      breathing tests, and administration of quality-of-life questionnaires. Subjects will then
      receive placebo or sildenafil (whichever one they did not receive for the first 4 weeks) for
      another 4 weeks, followed by the same testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Distance</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>The distance a subject walked within 6 minutes was measured and documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 Peak (Oxygen Consumption at Peak Exercise)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Oxygen consumption at peak exercise was measured at scheduled timepoints during treatment periods 1 and 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function FVC (Forced Vital Capacity)</measure>
    <time_frame>Period 1 (4 weeks)</time_frame>
    <description>Data to calculate results for FVC was based on Period 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in the First Second (FEV1 )</measure>
    <time_frame>Period 1 ( 4 weeks)</time_frame>
    <description>The volume of air exhaled in the first second. Data to calculate results for FEV1 was based on Period 1 only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnea(Scale That Measures Breathlessness) Score at Finish of 6 Minute Walk Test (6MWT)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Participants were asked to scale the breathlessness felt at the end of 6MWT from 0 to 10, with 0 being the least discomfort and 10 being the most discomfort in breathing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusing Capacity of Carbon Monoxide (DLCO)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Carbon Monoxide Diffusing Capacity was measured on the same days as the pulmonary function tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Pressure of Carbon Dioxide (PCO2) in Arterial Blood Gas (ABG)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Partial pressure of carbon dioxide in ABG performed breathing room air at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Pressure of Oxygen (PO2) in Arterial Blood Gas (ABG)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Partial Pressure of Oxygen in ABG breathing room air at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A-a Gradient (Alveolar-arterial Gradient)</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>A-a gradient was measured with ABG breathing room air at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Pulse</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>Oxygen pulse during Cardiopulmonary exercise test at peak exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O2 Saturation at Peak Exercise</measure>
    <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
    <description>O2 Saturation at Peak Exercise measured during the Cardiopulmonary exercise test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Sildenafil / Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil first, followed by washout, followed by placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Sildenafil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo first, followed by washout, followed by Sildenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>sildenafil citrate 25 mg by mouth thrice daily (po tid)</description>
    <arm_group_label>Sildenafil / Placebo</arm_group_label>
    <arm_group_label>Placebo / Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>25 mg po tid</description>
    <arm_group_label>Sildenafil / Placebo</arm_group_label>
    <arm_group_label>Placebo / Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema

          -  FEV1/FVC ratio &lt; 70%

          -  FEV1 &lt; 80%

          -  Stable medication regimen

        Exclusion Criteria:

          -  COPD exacerbation or hospitalization in the past 3 months

          -  Heart disease

          -  Contraindication to sildenafil

          -  Unrelated lung disease

          -  Inability to walk or pedal on a stationary bike

          -  Pregnancy or breast-feeding

          -  Pulmonary hypertension at rest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia Univeristy, College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <results_first_submitted>April 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2012</results_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Phosphodiesterase inhibitors</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Exercise testing</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period began in February 2005 and ended by November 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil /Placebo</title>
          <description>25 mg sildenafil is taken by mouth 3 times a day for 14 days followed by one week washout and then 25 mg placebo by mouth 3 times daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo /Sildenafil</title>
          <description>25 mg placebo is taken by mouth 3 times a day for 14 days followed by one week washout and then 25 mg sildenafil by mouth 3 times daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: ( TREATMENT: 4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (WASHOUT: 1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 ( TREATMENT: 4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Participants</title>
          <description>All enrolled and randomized participants who were administered 25 mg Sildenafil and 25mg placebo at 2 different time periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function FVC (Forced Vital Capacity)</title>
        <description>Data to calculate results for FVC was based on Period 1.</description>
        <time_frame>Period 1 (4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function FVC (Forced Vital Capacity)</title>
          <description>Data to calculate results for FVC was based on Period 1.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.2" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.2" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Minute Walk Distance</title>
        <description>The distance a subject walked within 6 minutes was measured and documented.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Distance</title>
          <description>The distance a subject walked within 6 minutes was measured and documented.</description>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.2" lower_limit="380" upper_limit="536"/>
                    <measurement group_id="O2" value="466.1" lower_limit="388" upper_limit="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VO2 Peak (Oxygen Consumption at Peak Exercise)</title>
        <description>Oxygen consumption at peak exercise was measured at scheduled timepoints during treatment periods 1 and 3.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>VO2 Peak (Oxygen Consumption at Peak Exercise)</title>
          <description>Oxygen consumption at peak exercise was measured at scheduled timepoints during treatment periods 1 and 3.</description>
          <units>ml/kg/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="10.3" upper_limit="17.0"/>
                    <measurement group_id="O2" value="13.8" lower_limit="10.3" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in the First Second (FEV1 )</title>
        <description>The volume of air exhaled in the first second. Data to calculate results for FEV1 was based on Period 1 only.</description>
        <time_frame>Period 1 ( 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in the First Second (FEV1 )</title>
          <description>The volume of air exhaled in the first second. Data to calculate results for FEV1 was based on Period 1 only.</description>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.7" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Dyspnea(Scale That Measures Breathlessness) Score at Finish of 6 Minute Walk Test (6MWT)</title>
        <description>Participants were asked to scale the breathlessness felt at the end of 6MWT from 0 to 10, with 0 being the least discomfort and 10 being the most discomfort in breathing.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Group that received Sildenafil</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Dyspnea(Scale That Measures Breathlessness) Score at Finish of 6 Minute Walk Test (6MWT)</title>
          <description>Participants were asked to scale the breathlessness felt at the end of 6MWT from 0 to 10, with 0 being the least discomfort and 10 being the most discomfort in breathing.</description>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.8" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diffusing Capacity of Carbon Monoxide (DLCO)</title>
        <description>Carbon Monoxide Diffusing Capacity was measured on the same days as the pulmonary function tests.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Diffusing Capacity of Carbon Monoxide (DLCO)</title>
          <description>Carbon Monoxide Diffusing Capacity was measured on the same days as the pulmonary function tests.</description>
          <units>ml/min/torr</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.1" upper_limit="15"/>
                    <measurement group_id="O2" value="11" lower_limit="7.1" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Pressure of Carbon Dioxide (PCO2) in Arterial Blood Gas (ABG)</title>
        <description>Partial pressure of carbon dioxide in ABG performed breathing room air at rest.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Pressure of Carbon Dioxide (PCO2) in Arterial Blood Gas (ABG)</title>
          <description>Partial pressure of carbon dioxide in ABG performed breathing room air at rest.</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="38" upper_limit="45"/>
                    <measurement group_id="O2" value="40" lower_limit="36" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Pressure of Oxygen (PO2) in Arterial Blood Gas (ABG)</title>
        <description>Partial Pressure of Oxygen in ABG breathing room air at rest.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Pressure of Oxygen (PO2) in Arterial Blood Gas (ABG)</title>
          <description>Partial Pressure of Oxygen in ABG breathing room air at rest.</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="66" upper_limit="79"/>
                    <measurement group_id="O2" value="77" lower_limit="71" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A-a Gradient (Alveolar-arterial Gradient)</title>
        <description>A-a gradient was measured with ABG breathing room air at rest.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants that received Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>A-a Gradient (Alveolar-arterial Gradient)</title>
          <description>A-a gradient was measured with ABG breathing room air at rest.</description>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="O2" value="23" lower_limit="16" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Pulse</title>
        <description>Oxygen pulse during Cardiopulmonary exercise test at peak exercise.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Pulse</title>
          <description>Oxygen pulse during Cardiopulmonary exercise test at peak exercise.</description>
          <units>ml/beat</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.4" upper_limit="11.0"/>
                    <measurement group_id="O2" value="9.5" lower_limit="7.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>O2 Saturation at Peak Exercise</title>
        <description>O2 Saturation at Peak Exercise measured during the Cardiopulmonary exercise test.</description>
        <time_frame>Period 1 and Period 3 ( within 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil citrate 25 mg by mouth three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo by mouth three times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>O2 Saturation at Peak Exercise</title>
          <description>O2 Saturation at Peak Exercise measured during the Cardiopulmonary exercise test.</description>
          <units>percentage of oxygen saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O2" value="96" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <desc>Adverse events were monitored during the clinical trial period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil</title>
          <description>25 mg sildenafil is taken by mouth 3 times a day for 14 days followed by one week washout and then 25 mg placebo by mouth 3 times daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>25 mg placebo is taken by mouth 3 times a day for 14 days followed by one week washout and then 25 mg sildenafil by mouth 3 times daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Facial Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rib Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respirartory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study had slow enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David J. Lederer, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-7771</phone>
      <email>dl427@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

